Literature DB >> 5085241

A study of clofazimine in the rat.

H L Currey, P D Fowler.   

Abstract

1. Clofazimine, an anti-mycobacterial agent used in the treatment of leprosy, has been reported to be particularly effective in the treatment of acute erythema nodosum leprosum reactions.2. The present experiments were designed to study in the rat this apparent anti-inflammatory activity.3. In doses relatively non-toxic to the animals clofazimine inhibited both rat adjuvant arthritis and the inflammatory paw swelling following an adjuvant injection.4. Clofamizine failed to inhibit both the primary antibody response to sheep erythrocytes and the tuberculin skin response.5. It is concluded that clofazimine exhibits definite anti-inflammatory (but not immunosuppressive) activity, and that it should be tested in patients with rheumatoid arthritis.

Entities:  

Mesh:

Substances:

Year:  1972        PMID: 5085241      PMCID: PMC1665956          DOI: 10.1111/j.1476-5381.1972.tb08126.x

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  9 in total

1.  TREATMENT OF LEPROSY WITH B 663 APPRAISAL OF THE PILOT TRIAL AFTER THREE YEARS.

Authors:  S G BROWNE
Journal:  Lepr Rev       Date:  1965-01       Impact factor: 0.537

2.  "B 663" in the treatment of leprosy. Preliminary report of a pilot trial.

Authors:  S G BROWNE; L M HOGERZEIL
Journal:  Lepr Rev       Date:  1962-01       Impact factor: 0.537

3.  A treatment of corticosteroid-dependent lepromatous patients in persistent erythema nodosum leprosum. A clinical evaluation of G.30320 (B663).

Authors:  F M Imkamp
Journal:  Lepr Rev       Date:  1968-07       Impact factor: 0.537

4.  Rimino-phenazines and the reticulo-endothelial system.

Authors:  M L Conalty
Journal:  Ir J Med Sci       Date:  1966-11       Impact factor: 1.568

5.  A preliminary report on the use of B663 in the treatment of Chinese leprosy patients with chronic reaction.

Authors:  A G Warren
Journal:  Lepr Rev       Date:  1968-04       Impact factor: 0.537

6.  Evaluation of B.663 in human leprosy.

Authors:  A J Atkinson; J N Sheagren; J B Rubio; V Knight
Journal:  Int J Lepr Other Mycobact Dis       Date:  1967 Apr-Jun

7.  Leprosy research at the National Institutes of Health: experience with B.663 in the treatment of leprosy.

Authors:  T W Williams; P D Mott; P T Wertlake; J B Rubio; R C Adler; G J Hill; G P Suarez; V Knight
Journal:  Int J Lepr       Date:  1965 Jul-Sep

8.  The experimental properties of G 30 320 (B 663)--a new anti-leprotic agent.

Authors:  W A Vischer
Journal:  Lepr Rev       Date:  1969-04       Impact factor: 0.537

9.  Suppression of adjuvant disease in the rat by heterologous antilymphocyte globulin.

Authors:  H L Currey; M Ziff
Journal:  J Exp Med       Date:  1968-01-01       Impact factor: 14.307

  9 in total
  3 in total

Review 1.  [Positive side-effects of antibiotic and antimicrobial drugs in therapy (author's transl)].

Authors:  L Illig
Journal:  Infection       Date:  1979       Impact factor: 3.553

2.  Use of thalidomide in leprosy.

Authors:  M Hooper
Journal:  BMJ       Date:  1991-11-30

3.  Modifications in the establishment of allergic encephalomyelitis (EAE) in rats; an imporved assay for immunosuppressant drugs.

Authors:  F W Beck; M W Whitehouse
Journal:  Agents Actions       Date:  1976-07
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.